# Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

> **NCT05889351** · PHASE2 · COMPLETED · sponsor: **Pharma Holdings AS** · enrollment: 27 (actual)

## Conditions studied

- Nasal Decolonization of Staphylococcus Aureus

## Interventions

- **DRUG:** Vehicle gel, 4 + 4 applications or 4 + 2 applications
- **DRUG:** LTX-109 3% gel, 4 + 4 applications
- **DRUG:** LTX-109 3% gel, 4 + 2 applications

## Key facts

- **NCT ID:** NCT05889351
- **Lead sponsor:** Pharma Holdings AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-10-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889351, "Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05889351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*